Combating multidrug-resistant pathogens with host-directed nonantibiotic therapeutics

Jourdan A. Andersson, Jian Sha, Michelle L. Kirtley, Emily Reyes, Eric C. Fitts, Sara Dann-Grice, Ashok Chopra

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Earlier, we reported that three Food and Drug Administration-approved drugs, trifluoperazine (TFP; an antipsychotic), amoxapine (AXPN; an antidepressant), and doxapram (DXP; a breathing stimulant), identified from an in vitro murine macrophage cytotoxicity screen, provided mice with 40 to 60% protection against pneumonic plague when administered at the time of infection for 1 to 3 days. In the present study, the therapeutic potential of these drugs against pneumonic plague in mice was further evaluated when they were administered at up to 48 h postinfection. While the efficacy of TFP was somewhat diminished as treatment was delayed to 24 h, the protection of mice with AXPN and DXP increased as treatment was progressively delayed to 24 h. At 48 h postinfection, these drugs provided the animals with significant protection (up to 100%) against challenge with the agent of pneumonic or bubonic plague when they were administered in combination with levofloxacin. Likewise, when they were used in combination with vancomycin, all three drugs provided mice with 80 to 100% protection from fatal oral Clostridium difficile infection when they were administered at 24 h postinfection. Furthermore, AXPN provided 40 to 60% protection against respiratory infection with Klebsiella pneumoniae when it was administered at the time of infection or at 24 h postinfection. Using the same in vitro cytotoxicity assay, we identified an additional 76/780 nonantibiotic drugs effective against K. pneumoniae. For Acinetobacter baumannii, 121 nonantibiotic drugs were identified to inhibit bacterium-induced cytotoxicity in murine macrophages. Of these 121 drugs, 13 inhibited the macrophage cytotoxicity induced by two additional multiple-antibiotic-resistant strains. Six of these drugs decreased the intracellular survival of all three A. baumannii strains in macrophages. These results provided further evidence of the broad applicability and utilization of drug repurposing screening to identify new therapeutics to combat multidrug-resistant pathogens of public health concern.

Original languageEnglish (US)
Article numbere01943
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Plague
Pharmaceutical Preparations
Macrophages
Acinetobacter baumannii
Klebsiella pneumoniae
Therapeutics
Amoxapine
Doxapram
Drug Repositioning
Clostridium Infections
Trifluoperazine
Levofloxacin
Preclinical Drug Evaluations
Clostridium difficile
United States Food and Drug Administration
Vancomycin
Infection
Respiratory Tract Infections
Antidepressive Agents
Antipsychotic Agents

Keywords

  • Acinetobacter baumannii
  • Bubonic plague
  • Clostridium difficile
  • In vitro assays
  • Klebsiella pneumoniae
  • Mouse models
  • New therapeutics
  • Pneumonic plague
  • Yersinia pestis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Combating multidrug-resistant pathogens with host-directed nonantibiotic therapeutics. / Andersson, Jourdan A.; Sha, Jian; Kirtley, Michelle L.; Reyes, Emily; Fitts, Eric C.; Dann-Grice, Sara; Chopra, Ashok.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 1, e01943, 01.01.2018.

Research output: Contribution to journalArticle

@article{a89a802de2a54515925697b20722cb11,
title = "Combating multidrug-resistant pathogens with host-directed nonantibiotic therapeutics",
abstract = "Earlier, we reported that three Food and Drug Administration-approved drugs, trifluoperazine (TFP; an antipsychotic), amoxapine (AXPN; an antidepressant), and doxapram (DXP; a breathing stimulant), identified from an in vitro murine macrophage cytotoxicity screen, provided mice with 40 to 60{\%} protection against pneumonic plague when administered at the time of infection for 1 to 3 days. In the present study, the therapeutic potential of these drugs against pneumonic plague in mice was further evaluated when they were administered at up to 48 h postinfection. While the efficacy of TFP was somewhat diminished as treatment was delayed to 24 h, the protection of mice with AXPN and DXP increased as treatment was progressively delayed to 24 h. At 48 h postinfection, these drugs provided the animals with significant protection (up to 100{\%}) against challenge with the agent of pneumonic or bubonic plague when they were administered in combination with levofloxacin. Likewise, when they were used in combination with vancomycin, all three drugs provided mice with 80 to 100{\%} protection from fatal oral Clostridium difficile infection when they were administered at 24 h postinfection. Furthermore, AXPN provided 40 to 60{\%} protection against respiratory infection with Klebsiella pneumoniae when it was administered at the time of infection or at 24 h postinfection. Using the same in vitro cytotoxicity assay, we identified an additional 76/780 nonantibiotic drugs effective against K. pneumoniae. For Acinetobacter baumannii, 121 nonantibiotic drugs were identified to inhibit bacterium-induced cytotoxicity in murine macrophages. Of these 121 drugs, 13 inhibited the macrophage cytotoxicity induced by two additional multiple-antibiotic-resistant strains. Six of these drugs decreased the intracellular survival of all three A. baumannii strains in macrophages. These results provided further evidence of the broad applicability and utilization of drug repurposing screening to identify new therapeutics to combat multidrug-resistant pathogens of public health concern.",
keywords = "Acinetobacter baumannii, Bubonic plague, Clostridium difficile, In vitro assays, Klebsiella pneumoniae, Mouse models, New therapeutics, Pneumonic plague, Yersinia pestis",
author = "Andersson, {Jourdan A.} and Jian Sha and Kirtley, {Michelle L.} and Emily Reyes and Fitts, {Eric C.} and Sara Dann-Grice and Ashok Chopra",
year = "2018",
month = "1",
day = "1",
doi = "10.1128/AAC.01943-17",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Combating multidrug-resistant pathogens with host-directed nonantibiotic therapeutics

AU - Andersson, Jourdan A.

AU - Sha, Jian

AU - Kirtley, Michelle L.

AU - Reyes, Emily

AU - Fitts, Eric C.

AU - Dann-Grice, Sara

AU - Chopra, Ashok

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Earlier, we reported that three Food and Drug Administration-approved drugs, trifluoperazine (TFP; an antipsychotic), amoxapine (AXPN; an antidepressant), and doxapram (DXP; a breathing stimulant), identified from an in vitro murine macrophage cytotoxicity screen, provided mice with 40 to 60% protection against pneumonic plague when administered at the time of infection for 1 to 3 days. In the present study, the therapeutic potential of these drugs against pneumonic plague in mice was further evaluated when they were administered at up to 48 h postinfection. While the efficacy of TFP was somewhat diminished as treatment was delayed to 24 h, the protection of mice with AXPN and DXP increased as treatment was progressively delayed to 24 h. At 48 h postinfection, these drugs provided the animals with significant protection (up to 100%) against challenge with the agent of pneumonic or bubonic plague when they were administered in combination with levofloxacin. Likewise, when they were used in combination with vancomycin, all three drugs provided mice with 80 to 100% protection from fatal oral Clostridium difficile infection when they were administered at 24 h postinfection. Furthermore, AXPN provided 40 to 60% protection against respiratory infection with Klebsiella pneumoniae when it was administered at the time of infection or at 24 h postinfection. Using the same in vitro cytotoxicity assay, we identified an additional 76/780 nonantibiotic drugs effective against K. pneumoniae. For Acinetobacter baumannii, 121 nonantibiotic drugs were identified to inhibit bacterium-induced cytotoxicity in murine macrophages. Of these 121 drugs, 13 inhibited the macrophage cytotoxicity induced by two additional multiple-antibiotic-resistant strains. Six of these drugs decreased the intracellular survival of all three A. baumannii strains in macrophages. These results provided further evidence of the broad applicability and utilization of drug repurposing screening to identify new therapeutics to combat multidrug-resistant pathogens of public health concern.

AB - Earlier, we reported that three Food and Drug Administration-approved drugs, trifluoperazine (TFP; an antipsychotic), amoxapine (AXPN; an antidepressant), and doxapram (DXP; a breathing stimulant), identified from an in vitro murine macrophage cytotoxicity screen, provided mice with 40 to 60% protection against pneumonic plague when administered at the time of infection for 1 to 3 days. In the present study, the therapeutic potential of these drugs against pneumonic plague in mice was further evaluated when they were administered at up to 48 h postinfection. While the efficacy of TFP was somewhat diminished as treatment was delayed to 24 h, the protection of mice with AXPN and DXP increased as treatment was progressively delayed to 24 h. At 48 h postinfection, these drugs provided the animals with significant protection (up to 100%) against challenge with the agent of pneumonic or bubonic plague when they were administered in combination with levofloxacin. Likewise, when they were used in combination with vancomycin, all three drugs provided mice with 80 to 100% protection from fatal oral Clostridium difficile infection when they were administered at 24 h postinfection. Furthermore, AXPN provided 40 to 60% protection against respiratory infection with Klebsiella pneumoniae when it was administered at the time of infection or at 24 h postinfection. Using the same in vitro cytotoxicity assay, we identified an additional 76/780 nonantibiotic drugs effective against K. pneumoniae. For Acinetobacter baumannii, 121 nonantibiotic drugs were identified to inhibit bacterium-induced cytotoxicity in murine macrophages. Of these 121 drugs, 13 inhibited the macrophage cytotoxicity induced by two additional multiple-antibiotic-resistant strains. Six of these drugs decreased the intracellular survival of all three A. baumannii strains in macrophages. These results provided further evidence of the broad applicability and utilization of drug repurposing screening to identify new therapeutics to combat multidrug-resistant pathogens of public health concern.

KW - Acinetobacter baumannii

KW - Bubonic plague

KW - Clostridium difficile

KW - In vitro assays

KW - Klebsiella pneumoniae

KW - Mouse models

KW - New therapeutics

KW - Pneumonic plague

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=85039797091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039797091&partnerID=8YFLogxK

U2 - 10.1128/AAC.01943-17

DO - 10.1128/AAC.01943-17

M3 - Article

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

M1 - e01943

ER -